Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

In patients with acute myeloid leukemia evolving from myeloproliferative neoplasms (post–MPN-AML), the clinical activity of the B-cell lymphoma 2 inhibitor venetoclax remains to be determined. We review our experience with venetoclax-based regimens in 14 newly diagnosed (frontline [FL]) and 17 relap...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood Adv
Главные авторы: Masarova, Lucia, DiNardo, Courtney D., Bose, Prithviraj, Pemmaraju, Naveen, Daver, Naval G., Kadia, Tapan M., Chifotides, Helen T., Zhou, Lingsha, Borthakur, Gautam, Estrov, Zeev, Konopleva, Marina, Verstovsek, Srdan
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2021
Предметы:
Myeloid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8095138/
https://ncbi.nlm.nih.gov/pubmed/33885751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003934
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы